Trinity Biotech plc (NASDAQ:TRIB) Short Interest Update

Trinity Biotech plc (NASDAQ:TRIBGet Rating) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 181,200 shares, a drop of 23.2% from the March 15th total of 235,800 shares. Based on an average trading volume of 125,200 shares, the short-interest ratio is currently 1.4 days.

TRIB stock opened at $1.22 on Monday. Trinity Biotech has a 12-month low of $0.86 and a 12-month high of $4.01. The stock has a market cap of $25.50 million, a price-to-earnings ratio of 13.56 and a beta of 1.55. The business’s 50-day moving average is $1.07 and its 200 day moving average is $1.49.

Trinity Biotech (NASDAQ:TRIBGet Rating) last posted its quarterly earnings data on Monday, April 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.13). Trinity Biotech had a negative return on equity of 3,160.63% and a negative net margin of 7.42%.

TRIB has been the topic of a number of analyst reports. TheStreet cut Trinity Biotech from a “c-” rating to a “d-” rating in a research report on Monday, December 20th. StockNews.com began coverage on Trinity Biotech in a research report on Monday, April 11th. They set a “buy” rating on the stock.

A number of hedge funds have recently bought and sold shares of the stock. Hunter Associates Investment Management LLC boosted its holdings in Trinity Biotech by 9.1% in the 4th quarter. Hunter Associates Investment Management LLC now owns 2,286,150 shares of the company’s stock worth $3,269,000 after buying an additional 190,250 shares during the last quarter. Envestnet Asset Management Inc. purchased a new position in Trinity Biotech in the 4th quarter worth approximately $159,000. LPL Financial LLC lifted its stake in Trinity Biotech by 20.1% in the 4th quarter. LPL Financial LLC now owns 106,973 shares of the company’s stock worth $153,000 after purchasing an additional 17,900 shares in the last quarter. Millennium Management LLC purchased a new position in Trinity Biotech in the 3rd quarter worth approximately $139,000. Finally, Whitefort Capital Management LP purchased a new position in Trinity Biotech in the 4th quarter worth approximately $50,000. Institutional investors own 27.83% of the company’s stock.

Trinity Biotech Company Profile (Get Rating)

Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. It operates through the Americas and Rest of World geographical segments. The company was founded by Ronan O’Caoimh and Denis R.

Featured Stories

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.